Merck (MRK) Report on the results of Q2 2025

Cripple On Tuesday, he said that he would reduce $ 3 billion in costs by the end of 2027 to be completely reinvested to support the launching of new products and its pipeline of drugs.

The multi -year effort comes while Merck is preparing to compensate for the loss of income for the expiration of future patents of his medicine against cancer of Keytruda cancer in 2028.

The shares of the pharmaceutical giant fell by approximately 3% in premature exchanges on Tuesday.

“Today, we have announced a multi -year optimization initiative that will redirect investments and more mature domain resources from our activities to our emerging range of new growth engines, will also allow the transformation of our portfolio, and stimulates our next chapter of productive growth and innovation,” said the CEO of Merck Rob Davis in the remarks prepared for the call for the purchase of Company.

He added that his confidence in Merck’s ability to navigate the loss of exclusivity of Keytruda increases with each new launch of products, data reading and commercial affairs. Davis said he considered this expiration of patents “as more than a hill than a cliff, and I am confident in our ability to grow in the long term”.

As part of the effort, Merck in July approved a new restructuring program that will eliminate certain administrative, sales and research and development positions. But the company will continue to hire employees in new roles in the growth fields of its business. Merck will also reduce its global property footprint and will continue to reduce its manufacturing network.

Merck expects actions as part of the restructuring program to generate approximately $ 1.7 billion in annual savings, most of which will start by the end of 2027.

The company expects the costs of pre-taxes linked to the restructuring program to be around $ 3 billion in total. For its second quarter, Merck recorded a charge of $ 649 million linked to the program.

Also on Tuesday, Merck reported the second quarter income which were not estimates of Wall Street. It was the first time that Metric has lacked expectations since April 2021.

While Keytruda sales increased during the period, Merck continued to see problems with Gardasil China sales, a vaccine that prevents HPV cancer, the most common sexually transmitted infection in the United States

In February, Merck announced the decision to stop the Gardasil expeditions to China from this month and spend at least mid-201. In prepared remarks, the director Caroline Litchfield said that the company would not resume shipments in China until the end of 2025, noting that stocks remain high and that the demand is still soft.

The company has also reduced its directives in the full year. Merck is now expecting its profits adjusted in 2025 to be between $ 8.87 and $ 8.97 per share. This is compared to its previous prospects from $ 8.82 to $ 8.97 per share.

Merck expects revenues for the year to be between $ 64.3 billion and $ 65.3 billion, reduced to the two ends of its previous forecasts of $ 64.1 billion to $ 65.6 billion.

Here is what Merck has reported for the second quarter compared to what Wall Street was expecting, on the basis of a survey of LSEG analysts:

• Profit by action: $ 2.13 adjusted. This figure may not be comparable to estimates of $ 2.01.
• Income: $ 15.81 billion against $ 15.89 billion expected

Merck has said that its directives include the previously estimated impact of $ 200 million associated with the prices that Trump has implemented to date. In April, the company declared that the expected tariff burden mainly reflected the samples between the United States and China, but did not take into account pharmaceutical prices specific to the sector.

The prospects also include unique costs related to the company’s license agreements with Hengrui Pharma and Lanova, but not its recently announced acquisition of Verona Pharma.

The company posted a net profit of $ 4.43 billion, or $ 1.76 per share, for the quarter. This is compared to the net income of $ 5.46 billion, or $ 2.14 per share, during the annual period.

By excluding acquisition and restructuring costs, Merck won $ 2.13 per share for the second quarter. This includes a load of 7 cents per share for the closing of the license contract with Hengrui Pharma.

Merck collected $ 15.81 billion in revenue for the quarter, down 2% compared to the same period a year ago.

The pharmaceutical unit of Merck, which develops a wide range of drugs, has reserved $ 14.05 billion in revenues during the second quarter. It is down 2% compared to the same period a year earlier.

Keytruda recorded $ 7.96 billion in revenue during the quarter, up 9% compared to the annual period.

This increase was motivated by a higher absorption of Keytruda for cancers at an anterior stage and a high demand for medication for metastatic cancers, which propagate to other parts of the body, the company said. Analysts expected the medication to contain $ 7.9 billion in sales, according to Streetaccount estimates.

Gardasil generated sales of $ 1.13 billion for the quarter, down 55% compared to the same period a year ago due to the drop in demand in China. Analysts expected Gardasil to reserve sales of $ 1.33 billion, according to Streetaccount, according to estimates.

The Chinese market is the majority of international revenues of the blockbuster. Merck hopes that the extended approval of Gardasil for men aged 9 to 26 in China will help increase the adoption of the vaccine.

Gardasil sales in the United States increased by 2% in the second quarter.

Meanwhile, the new Winrevair medication of Merck, which is used to treat a rare and fatal pulmonary condition, recorded $ 336 million in sales for the quarter. Analysts expected the medication to bring $ 324.7 million, according to Streetaccount estimates.

The Merck animal health division, which develops vaccines and dogs for dogs, cats and cattle, posted nearly $ 1.65 billion in sales, up 11% compared to the same period a year earlier. The company said that the higher demand for farming and sales products from the Elanco Aqua company, which it acquired last year, led this growth.